Valneva (NASDAQ:VALN) Posts Earnings Results

Valneva (NASDAQ:VALN) posted its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.17), Zacks reports. The business had revenue of $39.37 million during the quarter, compared to the consensus estimate of $43.15 million. Valneva had a negative return on equity of 142.99% and a negative net margin of 110.33%.

Here are the key takeaways from Valneva’s conference call:

• Lyme vaccine regulatory progress advanced: Pfizer has filed the candidate with the European Medicines Agency and is working with the FDA toward a planned BLA submission, with regulatory decisions expected within the next 12 months. Valneva highlighted efficacy above 70%, though the initial analysis missed the lower bound of its confidence interval.
• Valneva ended the first half with €121.5 million in cash and reaffirmed 2026 product-sales guidance of €135 million–€150 million and total-revenue guidance of €145 million–€160 million. Restructuring and cost-saving measures are expected to improve cash flow and earnings in the second half and beyond.
• First-half product sales fell to €64 million from €91 million, while total revenue declined to €65.8 million from €97.6 million. The operating loss widened to €49.9 million and adjusted EBITDA loss to €40.1 million, partly due to lower sales and one-time IXCHIQ manufacturing cancellation fees and inventory impairment.
• IXCHIQ travel-market uptake remains slow, prompting Valneva to evaluate a greater focus on endemic markets. Brazil has approved Butantan’s locally manufactured version, and a government pilot campaign has vaccinated more than 50,000 people, with a target of at least 100,000.
• Results from the shigella vaccine’s infant immunogenicity/safety study and adult human-challenge study are expected in the coming months. Valneva will use the data to determine whether to advance or optimize the program’s dose, schedule, or formulation.

Valneva Stock Performance

Shares of NASDAQ:VALN opened at $7.13 on Friday. The company has a current ratio of 2.14, a quick ratio of 1.60 and a debt-to-equity ratio of 2.14. Valneva has a 12 month low of $4.75 and a 12 month high of $12.25. The company has a market capitalization of $676.57 million, a price-to-earnings ratio of -3.38 and a beta of 1.77. The firm’s 50-day moving average is $5.24 and its 200 day moving average is $6.92.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Marex Group plc purchased a new stake in shares of Valneva in the second quarter worth approximately $64,000. XTX Topco Ltd purchased a new position in Valneva during the 4th quarter valued at $94,000. Finally, JPMorgan Chase & Co. purchased a new position in Valneva during the 3rd quarter valued at $124,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva News Roundup

Here are the key news stories impacting Valneva this week:

• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s marketing authorization application for their six-valent Lyme disease vaccine candidate, PF-07307405. The validation allows the EMA to begin its formal assessment, a significant step toward potential approval and commercialization. The vaccine is being developed in partnership with Pfizer, with regulatory decisions potentially targeted within the next year. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: Investor attention is increasing around the potential Lyme vaccine market. Reports said the European Union will study the candidate, which could address an unmet need as Lyme disease cases rise and no broadly available human vaccine is currently marketed. EU to study potential vaccine for Lyme disease: companies
• Neutral Sentiment: TD Cowen initiated research coverage on Valneva. New analyst coverage may improve visibility, but the article did not provide a rating or price target that would establish a clear trading signal. Valneva Research Coverage Started at TD Cowen
• Negative Sentiment: Valneva’s second-quarter earnings missed expectations: the company reported a loss of $0.40 per share versus a consensus loss of $0.23, while revenue of $39.37 million fell short of the $43.15 million estimate. The company continues to report substantial losses, reflected in its negative net margin and return on equity. Valneva Earnings Results
• Neutral Sentiment: Management reaffirmed its 2026 financial outlook while emphasizing a strategic focus on commercial execution and the Lyme vaccine program. The guidance provides some visibility, but profitability and the timing of potential Lyme vaccine revenue remain uncertain. Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

Wall Street Analysts Forecast Growth

VALN has been the subject of a number of analyst reports. The Goldman Sachs Group downgraded shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target for the company. in a report on Wednesday, April 22nd. TD Cowen initiated coverage on Valneva in a research report on Tuesday. They set a “buy” rating and a $12.00 price objective on the stock. Wall Street Zen raised Valneva from a “strong sell” rating to a “sell” rating in a research note on Monday, June 1st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a report on Thursday, June 18th. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $11.98.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.